A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Recruiting now Phase 3 NCT07241390
Run by Eli Lilly and Company · for 50 and older · All sexes
What this study is about
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Who can join (things the study team will check)
✅ You may be able to join if…
- Have established ASCVD and/or CKD
🚫 You may not be able to join if…
- Have type 1 diabetes
- Have had a major heart condition within 60 days prior to screening
- Have New York Heart Association Functional Classification Class IV heart failure
Where this trial is running
- Instituto de Investigaciones Clínicas Bahia Blanca, Bahía Blanca, Argentina
- CONEXA Investigacion Clinica S.A., Buenos Aires, Argentina
- Buenos Aires Macula S.A, Buenos Aires, Argentina
- CIPREC, Buenos Aires, Argentina
- Instituto Médico Especializado (IME), Buenos Aires, Argentina
- Cicemo Srl, Buenos Aires, Argentina
- Cardiología Palermo, Buenos Aires, Argentina
- Consultorio Medico Investigador Principal Dr Besada, Buenos Aires, Argentina
- Glenny Corp. S.A., Buenos Aires, Argentina
- Organizacion Medica de Investigacion, Buenos Aires, Argentina
- Stat Research S.A., Buenos Aires, Argentina
- Investigaciones Medicas Imoba Srl, Buenos Aires, Argentina
+ 556 more sites.
Who to contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07241390.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.